Literature DB >> 30782989

Apotransferrin in Combination with Ciprofloxacin Slows Bacterial Replication, Prevents Resistance Amplification, and Increases Antimicrobial Regimen Effect.

Paul G Ambrose1,2, Brian D VanScoy1, Brian M Luna3,4, Jun Yan3,4, Amber Ulhaq3,4, Travis B Nielsen3,4, Sue Rudin5,6, Kristine Hujer5,6, Robert A Bonomo5,6,7, Luis Actis7, Eric Skaar8, Brad Spellberg9.   

Abstract

There has been renewed interest in combining traditional small-molecule antimicrobial agents with nontraditional therapies to potentiate antimicrobial effects. Apotransferrin, which decreases iron availability to microbes, is one such approach. We conducted a 48-h one-compartment in vitro infection model to explore the impact of apotransferrin on the bactericidal activity of ciprofloxacin. The challenge panel included four Klebsiella pneumoniae isolates with ciprofloxacin MIC values ranging from 0.08 to 32 mg/liter. Each challenge isolate was subjected to an ineffective ciprofloxacin monotherapy exposure (free-drug area under the concentration-time curve over 24 h divided by the MIC [AUC/MIC ratio] ranging from 0.19 to 96.6) with and without apotransferrin. As expected, the no-treatment and apotransferrin control arms showed unaltered prototypical logarithmic bacterial growth. We identified relationships between exposure and change in bacterial density for ciprofloxacin alone (R 2 = 0.64) and ciprofloxacin in combination with apotransferrin (R 2 = 0.84). Addition of apotransferrin to ciprofloxacin enabled a remarkable reduction in bacterial density across a wide range of ciprofloxacin exposures. For instance, at a ciprofloxacin AUC/MIC ratio of 20, ciprofloxacin monotherapy resulted in nearly 2 log10 CFU increase in bacterial density, while the combination of apotransferrin and ciprofloxacin resulted in 2 log10 CFU reduction in bacterial density. Furthermore, addition of apotransferrin significantly reduced the emergence of ciprofloxacin-resistant subpopulations compared to monotherapy. These data demonstrate that decreasing the rate of bacterial replication with apotransferrin in combination with antimicrobial therapy represents an opportunity to increase the magnitude of the bactericidal effect and to suppress the growth rate of drug-resistant subpopulations.
Copyright © 2019 American Society for Microbiology.

Entities:  

Keywords:  Klebsiellazzm321990; antibiotic resistance; ciprofloxacin; fluoroquinolone; transferrin

Year:  2019        PMID: 30782989      PMCID: PMC6496049          DOI: 10.1128/AAC.00112-19

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  13 in total

1.  Transferrin iron starvation therapy for lethal bacterial and fungal infections.

Authors:  Lin Lin; Paul Pantapalangkoor; Brandon Tan; Kevin W Bruhn; Tiffany Ho; Travis Nielsen; Eric P Skaar; Yaofang Zhang; Ruipeng Bai; Amy Wang; Terence M Doherty; Brad Spellberg
Journal:  J Infect Dis       Date:  2014-01-19       Impact factor: 5.226

2.  Bacterial Replication Rate Modulation in Combination with Antimicrobial Therapy: Turning the Microbe against Itself.

Authors:  Paul G Ambrose; Brian VanScoy; Haley Conde; Jennifer McCauley; Christopher M Rubino; Sujata M Bhavnani
Journal:  Antimicrob Agents Chemother       Date:  2016-12-27       Impact factor: 5.191

Review 3.  Bioenergetic challenges of microbial iron metabolisms.

Authors:  Lina J Bird; Violaine Bonnefoy; Dianne K Newman
Journal:  Trends Microbiol       Date:  2011-06-12       Impact factor: 17.079

4.  A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with beta-thalassemia.

Authors:  Maria Domenica Cappellini; Alan Cohen; Antonio Piga; Mohamed Bejaoui; Silverio Perrotta; Leyla Agaoglu; Yesim Aydinok; Antonis Kattamis; Yurdanur Kilinc; John Porter; Marcello Capra; Renzo Galanello; Slaheddine Fattoum; Guillermo Drelichman; Carmelo Magnano; Monica Verissimo; Miranda Athanassiou-Metaxa; Patricia Giardina; Alexandra Kourakli-Symeonidis; Gritta Janka-Schaub; Thomas Coates; Christiane Vermylen; Nancy Olivieri; Isabelle Thuret; Herbert Opitz; Catherine Ressayre-Djaffer; Peter Marks; Daniele Alberti
Journal:  Blood       Date:  2005-12-13       Impact factor: 22.113

Review 5.  Recombinant human transferrin: beyond iron binding and transport.

Authors:  Martin E Brandsma; Anthony M Jevnikar; Shengwu Ma
Journal:  Biotechnol Adv       Date:  2010-12-13       Impact factor: 14.227

6.  Pharmacological basis of β-lactamase inhibitor therapeutics: tazobactam in combination with Ceftolozane.

Authors:  Brian Vanscoy; Rodrigo E Mendes; Jennifer McCauley; Sujata M Bhavnani; Catharine C Bulik; Olanrewaju O Okusanya; Alan Forrest; Ronald N Jones; Lawrence V Friedrich; Judith N Steenbergen; Paul G Ambrose
Journal:  Antimicrob Agents Chemother       Date:  2013-09-16       Impact factor: 5.191

7.  Norepinephrine in Combination with Antibiotic Therapy Increases both the Bacterial Replication Rate and Bactericidal Activity.

Authors:  Paul G Ambrose; Brian D VanScoy; John Adams; Steven Fikes; Justin C Bader; Sujata M Bhavnani; Christopher M Rubino
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

8.  Apotransferrin administration prevents growth of Staphylococcus epidermidis in serum of stem cell transplant patients by binding of free iron.

Authors:  Leni von Bonsdorff; Leila Sahlstedt; Freja Ebeling; Tapani Ruutu; Jaakko Parkkinen
Journal:  FEMS Immunol Med Microbiol       Date:  2003-06-10

9.  Toxic DNA damage by hydrogen peroxide through the Fenton reaction in vivo and in vitro.

Authors:  J A Imlay; S M Chin; S Linn
Journal:  Science       Date:  1988-04-29       Impact factor: 47.728

Review 10.  Clinical application of deferasirox: practical patient management.

Authors:  Elliott Vichinsky
Journal:  Am J Hematol       Date:  2008-05       Impact factor: 10.047

View more
  2 in total

1.  Red blood cell transfusion-induced non-transferrin-bound iron promotes Pseudomonas aeruginosa biofilms in human sera and mortality in catheterized mice.

Authors:  Francesca La Carpia; Andrea Slate; Sheila Bandyopadhyay; Boguslaw S Wojczyk; Elizabeth A Godbey; Kevin P Francis; Kevin Prestia; Eldad A Hod
Journal:  Br J Haematol       Date:  2021-11-02       Impact factor: 6.998

Review 2.  Iron-withdrawing anti-infectives for new host-directed therapies based on iron dependence, the Achilles' heel of antibiotic-resistant microbes.

Authors:  Bruce E Holbein; M Trisha C Ang; David S Allan; Wangxue Chen; Christian Lehmann
Journal:  Environ Chem Lett       Date:  2021-04-23       Impact factor: 9.027

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.